KLA Stock Upgraded to Buy After July Pullback; Strong Revenue Guidance Offsets Margin Pressure

What happened

KLA shares suffered a punishing July, bringing the stock down from its June highs and improving the risk-reward from the perspective of valuation-sensitive investors. The company's fiscal Q4 revenue grew 15% year-over-year, but gross margin contracted, consistent with the previously flagged ~100 basis point headwind from elevated DRAM costs. Guidance for fiscal Q1 2027 calls for 25% revenue growth with stable gross margin, suggesting that top-line momentum is accelerating even as costs remain a headwind. Seeking Alpha upgraded KLA to a Buy following the pullback, citing robust semiconductor demand and the strong forward guidance as outweighing near-term margin pressure. Our deep-value analysis had rated KLA a WAIT at $271, but the recent decline may have pulled the stock closer to our attractive entry level of $220, warranting a reassessment.

Implication

The 25% revenue growth guidance for Q1 FY2027 is a positive surprise that suggests the semiconductor equipment upcycle remains robust, potentially supporting higher forward estimates. However, the gross margin decline in Q4 and only 'stable' guidance for Q1 means the company's profitability is not yet inflecting higher, keeping a lid on near-term earnings upside. The July selloff has likely improved the valuation, but KLA still trades at a premium multiple relative to the broader market, so a margin of safety only emerges if the price approaches our $220 target. Export-control risks remain a key wild card, and any escalation could dent China revenue (still ~30% of sales) and force deposit returns, which the market may not be fully pricing in. For now, we maintain a cautious stance: treat any further pullback as an opportunity, but avoid chasing strength until there is concrete evidence that gross margin is stabilizing above 60% and China exposure is declining.

Thesis delta

The July selloff has brought KLA's valuation closer to our $220 attractive entry, and the Q1 FY2027 guidance for 25% revenue growth exceeds our bull-case assumptions, shifting the risk-reward in a more favorable direction. However, the Q4 gross margin decline and only 'stable' margin guidance suggest that the earnings multiple may not expand until costs normalize, so we are not yet upgrading to an unqualified buy. We see the stock as a buy on weakness toward $220, but at current levels we remain disciplined and would trim above $310.